{"title": "PDF", "author": "PDF", "url": "www.hhs.gov/sites/default/files/2019-6-5%20NVAC_June2019_Remich.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "1 UPDATE: Vaccine Candidate Against C. difficile Shon Anthony Remich, MD Senior Director, Vaccine Clinical Research & Development Shon Anthony Remich, MD, is employed by Pfizer and owns stock in the company 2Currently, there is no vaccine to prevent initial or recurrent CDIIf Nothing Else, You Should Remember... CDI= Clostridium difficile infection. 1.Clostridium difficile Infections in Hospital Stays, 2009. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf. Accessed May 9, 2019. 2. Lessa FC, et al. N Engl J Med . 2015;372(24):2369-2370. 3. Centers for Disease Control and Prevention: Biggest threats and data. https://www.cdc.gov/drugresistance/biggest_threats.html. Accessed May 9, 2019. C. difficile bacteria express toxins, causing severe diarrhea1 Antibiotic use causes C. difficile Ages 1-17 yr 45-64 yr 18-44 yr 65 yrCDI incidence per 100,000 persons 100CDI Incidence in the US by Age Group (2011)1 Typical recommendation threshold (100 per 100k)A Nationwide Surveillance Program by the CDC Demonstrates That the Incidence of C. difficile Increases With Age 1. Lessa FC, et al. N Engl J Med . 2015;372(24):2369-2370. 2. Centers for Disease Control and Prevention: What is C. diff ?. https://www.cdc.gov/cdiff/what-is.html. Accessed May 9, 2019.1 in 11 patients aged 65 years died of healthcare-related CDI within 1 month of diagnosis24CDC Emerging Infections Program C. difficile US Surveillance Data: 2011 -2016 1. Lessa FC, et al. N Engl J Med. 2015;372(24):2369-2370. 2. Center of Disease Control and Prevention. Data Summary of HAIs in the US: Assessing Progress 2006-2016. Unpublished data (2016) courtesy of Dr. Alice Guh. No. of cases CDI Community Associated CDIReported Crude Incidence of Community -Associated and Healthcare -Associated CDIAmong the 10 Emerging Infections Program Sites, 2011 -20161,2 55.8 Healthcare - - Overall 3% decrease in CDI from 2011 to 2016219% decrease in healthcare -associated CDI from 2011 -20162 39% in community -associated 453,000 Implementation: Ease of manufacturing Toxin A Toxin BExpression in C. difficile Recipient VPI 11186 SPO -A and Toxin minus 6C. difficile Vaccine Clinical Development Program 1. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01706367. Accessed May 9, 2019. 2. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02725437. Accessed May 9, 2019. 3.ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02561195. Accessed May 9, 2019. 4. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03090191. Accessed May 9, 2019. 5. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03579459. Accessed May 14, 2019 . 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03918629. Accessed May 14, 2019.2015 2016 2017 2018 2019 20202012-2 013 Phase 1, n=192 (US) First-i n -human study at three dose levels, with or without adjuvant, to assess safety and tolerability in adults aged 50 to 85 years1Phase 1, n=100 (Japan) First-i n-Japan study of the safety, tolerability, and immunogenicity of 2 dose levels over 2 vaccination schedules of CDI vaccine in adults aged 65 to 85 years2 Phase 2, n=855 (US) Evaluation of the safety, tolerability, and immunogenicity of CDI vaccine in adults aged 65 to 85 years on two vaccination schedules, with or without an additional dose 1 year after third dose3 Clover, Phase 3, n~17.5k (Global) Safety, tolerability, and efficacy of CDI vaccine in adults aged 50 years4 Phase 3, n=1316 (US) Study to evaluate the lot consistency, safety, tolerability, and immunogenicity of CDI vaccine in adults aged 65 to 85 years5 Phase 3, n=500 (US) Study to evaluate the immuno- genicity, safety, and tolerability of a 2-dose CDI vaccine regimen compared to a 3-dose regimen in adults aged 50 years67CDI vaccine 100 \u00b5g (n=183) CDIvaccine 200 \u00b5g (n=183) Placebo (n=61) Month 0, period M0 M1 M6 M7 M12 M18Extension stage RandomizationProof of Concept Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of CDI Vaccine in Adults Aged (NCT02561195) g -Month 0, 1, 6) Range: 65-85 Mean: 71.3 65 placebo-controlled, randomized, observer-blinded study to evaluate the safety, of two 3-dose regimens of a Clostridium difficile vaccine in healthy adults 65 to 85 years of age. Poster presented at: ECCMID; April 21-24, 2018; Madrid, Spain. 9.8 19.7 8Month Regimen Geometric Mean Concentration (GMC) Levels (200 g vs Placebo) 0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540101001000GMC levels - Month Regimen (Toxin A) DaysGMC (neutralization units/mL)Placebo200g 0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540100100010000GMC levels - Month Regimen (Toxin B) DaysGMC (neutralization units/mL)200g Placebo Month 0, 1, 6 Schedule: Month 0, 1, 6 Schedule: Remich S, et al. A phase-2, placebo-controlled, randomized, observer-blinded study to evaluate the safety, of two 3-dose regimens of a Clostridium difficile vaccine in healthy adults 65 to 85 years of age. Poster presented at: ECCMID; April 21-24, 2018; Madrid, Spain.9E-diary Reported Events: Month 0, 1, 6 Regimen (Follow -up 14 Days After Each Dose) 0%10%20%30%40%50% Placebo 200 g Placebo 200 g Placebo 200 g Pain Redness SwellingPost dose 1 Local Reactions 0%10%20%30%40%50% Placebo 200 g Placebo 200 g Placebo 200 g Pain Redness SwellingPost dose 2 0%10%20%30%40%50% Placebo 200 g Placebo 200 g Placebo 200 g Pain Redness SwellingPost dose 3 Grade 1 (mild) Grade 2 (moderate) Grade 3 (severe) Grade 40%10%20%30%40% Placebo 200 g Placebo 200 g Fatigue HeadachePost dose 1 0%10%20%30%40% Placebo 200 g Placebo 200 g Fatigue HeadachePost dose 2 0%10%20%30%40% Placebo 200 g Placebo 200 g Fatigue HeadachePost dose 3 Fatigue and Headache Remich S, et al. A phase-2, placebo-controlled, randomized, observer-blinded study to evaluate the safety, of two 3-dose regimens of a Clostridium difficile vaccine in healthy adults 65 to 85 years of age. Poster presented at: ECCMID; April 21-24, 2018; Madrid, Spain. 10E-diary Reported Fever: Month 0, 1, 6 Regimen (Follow -up 14 Days After Each Dose) 0%1%2%3%4%5% Placebo 200 gPost dose 1 0%1%2%3%4%5% Placebo 200 gPost dose 2 study to evaluate the safety, of two 3-dose regimens of a Clostridium difficile vaccine in healthy adults 65 to 85 years of age. Poster presented at: ECCMID; April 21-24, 2018; Madrid, Spain. 11E-diary Reported Events: Month 0, 1, 6 Regimen (Follow -up 14 Days After Each Dose) 0%10%20%30% Placebo 200 g Placebo 200 g Diarrhea VomitingPost dose 1 0%10%20%30% Placebo 200 g Placebo 200 g Diarrhea VomitingPost dose 2 0%10%20%30% Placebo 200 g Placebo 200 g Diarrhea VomitingPost dose 3 0%10%20% Placebo 200 g Placebo 200 g Muscle pain Joint painPost dose 1 0%10%20% Placebo 200 g Placebo 200 g Muscle pain Joint painPost dose 2 0%10%20% Placebo 200 g Placebo 200 g Muscle pain Joint painPost dose 3 Grade 1 (mild) Grade 2 (moderate) Grade 3 (severe) Grade 4Diarrhea and vomiting Muscle pain and joint pain Remich S, et al. A phase-2, placebo-controlled, randomized, observer-blinded study to evaluate the safety, of two 3-dose regimens of a Clostridium difficile vaccine in healthy adults 65 to 85 years of age. Poster presented at: ECCMID; April 21-24, 2018; Madrid, Spain. 12020406080 Any AE Related AE Any SAE Related SAE Withdrawal due to AEWithdrawal due to AE (related)DeathProportion of subjects (%)200 g CDI vaccine PlaceboSafety Profile: Adverse Events and Serious Adverse Events Safety profile of 200 g dose at 0, 1, and 6 months in this phase 2 study is consistent with previous studies AE=adverse event; SAE=serious adverse event. Remich S, et al. A placebo-controlled, randomized, observer-blinded study to evaluate the safety, of two 3-dose regimens of a Clostridium difficile vaccine in healthy adults 65 to 85 years of age. Poster presented at: ECCMID; April 21-24, 2018; Madrid, Spain.14Subjects meeting all inclusion and no exclusion criteria~17.5k subjects Month 0 6 1Follow-up Period Up to 3 yearsVaccination Period 3 or more unformed stools (Bristol stool chart types 5-7) within 24 hoursInterim analysis: 63 casesEnrollment Final analysis: 106 cases Kentucky Brussels Singapore Diagnostic Assays 382 sites in 23 countriesClostridium Difficile Vaccine Efficacy Trial (Clover) 153 diarrheal episodes in 24 hrs Stool Collection: Home, Nursing Home, Clinic / Urgent Care, Hospital NanoCool Shipper 2-10 \u00b0C 96 hrs PPD Processing Lab Kentucky Belgium Singapore Central Testing Lab Pearl River, NYFrom Sample Collection to Diagnostic Testing Maintenance of Sample Cold Chain Custody Stool Sample PCR Cepheid GeneXpert \u00ae STEP 1 No Case- + Positive Case STEP 2 Perform and the FDA Diagnostic Testing 16Conclusions CDI causes significant disease in adults >50 years of age in community and hospital settings Pfizer's vaccine was produced using a novel detoxification process that preserves critical epitopes maximizing production of neutralizing antibodies The vaccine induces polyclonal antibodies that neutralize diverse toxins and shows protection in preclinical models Vaccine program has progressed through proof of concept to phase 3 demonstrating robust immune responses with a strong safety profile Status: phase 3 Clover trial is fully enrolled and awaiting case accrual17Acknowledgments We thank all of the study participants and the investigators for their substantial contributions to the enrollment of subjects and collection of data Pfizer Contributors Chris Webber Nick Kitchin Shon Remich Catia Ferreira Jody Lawrence Ping Li Stephen Lockhart Bill Gruber Michael Pride Kathrin Jansen "}